Epsilon M&A Deal Report - Fraxiparine and Arixtra brands of GSK and Associated Manufacturing Plant
Transaction Multiples for the Valuation of Private Companies
Aspen Pharmacare Holdings / Fraxiparine and Arixtra brands of GSK and Associated Manufacturing Plant
No EMAT :
62935
Announced Date :
30/09/2013
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Aspen Pharmacare Holdings
Target :
Fraxiparine and Arixtra brands of GSK and Associated Manufacturing Plant
Country :
France
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
Business Description :
Business comprises the branded products Fraxiparine/Fraxodi and Arixtra, both injectable anti-coagulants and the specialised sterile production site which manufactures the Brands at Notre Dame de...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|||||
| Current |
|
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
| Date | Acquirer | Target | Country | Multiples | See details |
| 22/05/2013 | Private Group led by Charterhouse Capital Partners LLP | DOC Generici | Italy | *** | 62906 |
| 17/01/2014 | Aurobindo Pharma | Actavis Generics Commercial Operations In Euro Zone Markets | France | ** | 62880 |
Source: Epsilon Research / EMAT
